Biotech Founder Makes Ethical Case for Embryo Gene Editing
The debate over editing human embryos has taken a new turn as biotech founder Cathy Tie, who leads Origin Genomics, publicly advocates for the practice as an ethical necessity rather than a line to be crossed.
Tie contends that the ability to eliminate hereditary diseases at the embryonic stage presents a moral obligation, framing the technology not as playing god but as a way to spare future generations from preventable suffering. Her position places her among those who see somatic gene therapies—currently approved for certain conditions—as insufficient for addressing genetic diseases before they manifest.
However, the scientific and ethical concerns surrounding germline editing remain substantial. Off-target effects, mosaicism, and the long-term consequences of heritable changes remain active areas of research. Beyond safety, critics raise questions about designer babies, equitable access, and whether the technology's benefits would reach all populations fairly.
The conversation reflects a broader tension in biotechnology: the line between eliminating devastating genetic conditions and inadvertently opening the door to enhancements that could reshape human traits beyond medical necessity.